Trial Profile
Efficacy and Safety of Thrombopoetin-Receptor Agonist Eltrombopag in in Combination With Ciclosporin A in Moderate Aplastic Anemia (EMAA): Prospective Randomized Multicenter Study
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Ciclosporin
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms EMAA
- 01 Feb 2018 Planned End Date changed from 1 Sep 2021 to 30 Sep 2023.
- 01 Feb 2018 Planned primary completion date changed from 1 Sep 2020 to 30 Sep 2022.
- 20 May 2016 New trial record